Ligand Pharmaceuticals saw a notable increase in stock value, reflecting positive market sentiment.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) experienced a gain of 3.09% in its stock price during yesterday's trading session, closing at CA$311.13. This upward movement may be attributed to the company's recent strategic developments and overall market performance.
Advertisement
Ligand Pharmaceuticals Incorporated
LGND.US
LGND.US
Ligand Pharmaceuticals Incorporated
WealthAwesomeMarket cap
$6.02B
P/E
31.8x
52W high
$326.63
52W low
$175.89
1W change
+1.42%
Beta
1.01
Analyst Price Targets
Based on 11 analysts covering LGND · as of Oct 5, 2026
Wall Street analysts forecast LGND stock price to rise 10.6% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
C$344.25
+10.6% Upside
Current Price
C$311.13
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LGND's historical volatility
30-Day Vol
28.9%
Annualized
90-Day Vol
33.8%
Annualized
Trend (90d)
+20.3%
Annualized drift
90d Mean
C$334.52
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$318.74 | C$288.54 – C$352.10 |
| 60 trading days | C$326.54 | C$283.66 – C$375.90 |
| 90 trading days | C$334.52 | C$281.54 – C$397.47 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find Ligand's recent gains encouraging, particularly in light of its ongoing expansion in the biopharmaceutical sector.
3.09%
Ligand's stock increased by 3.09% yesterday, reflecting positive investor sentiment.
Bull case
Ligand's recent financing agreement with AvenCell Therapeutics to advance CAR-T therapies and the acquisition of royalty interests show strong growth potential. These developments could significantly boost future revenue.
Bear case
Even with the recent gain, investors should remain cautious due to market volatility and the competitive landscape in the biopharmaceutical industry, which could affect Ligand's performance.
Advertisement
Recent Developments Fueling Growth
Ligand Pharmaceuticals has been actively expanding its portfolio through strategic acquisitions and financing agreements. Notably, the company entered a financing agreement with AvenCell Therapeutics, potentially worth up to $47 million, aimed at advancing next-generation CAR-T therapies. This move signals Ligand's commitment to innovation in the biopharmaceutical space.
Financial Performance and Market Position
Ligand's financial health remains strong, with a reported profit margin of 67.88% and a P/E ratio of 33.78. The company has shown a significant year-over-year increase in royalty revenue, reinforcing its position as a leading biopharma royalty aggregator. Investors may view this financial stability as a positive indicator for future growth.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
